EVO NASDAQ
Hamburg, HA 22419
DE
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Anderson Mark Monroe | A-Award | 100,000 | $2.50 | 2018-10-22 |
| Anderson Mark Monroe | 0 | — | 2018-10-22 | |
| QUINTON KEITH | 0 | — | 2018-10-01 | |
| Smith Marcus L. | 0 | — | 2018-10-01 | |
| Smith Scott Clifford | A-Award | 100,000 | $2.50 | 2018-08-13 |